| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 21 | 2024 | 745 | 1.990 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2024 | 258 | 1.200 |
Why?
|
| Ventricular Function, Left | 13 | 2021 | 520 | 1.050 |
Why?
|
| Point-of-Care Systems | 5 | 2020 | 150 | 0.920 |
Why?
|
| Trastuzumab | 2 | 2016 | 86 | 0.900 |
Why?
|
| Heart Diseases | 8 | 2022 | 257 | 0.900 |
Why?
|
| Aortic Diseases | 1 | 2024 | 87 | 0.780 |
Why?
|
| Heart Valve Diseases | 2 | 2024 | 100 | 0.780 |
Why?
|
| Cardiotoxicity | 2 | 2021 | 12 | 0.760 |
Why?
|
| Cardiology | 5 | 2023 | 120 | 0.760 |
Why?
|
| Heart Neoplasms | 2 | 2022 | 52 | 0.750 |
Why?
|
| Stroke Volume | 7 | 2021 | 438 | 0.740 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 2303 | 0.720 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 104 | 0.670 |
Why?
|
| Anthracyclines | 2 | 2019 | 31 | 0.590 |
Why?
|
| Medical Oncology | 7 | 2023 | 404 | 0.580 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 754 | 0.570 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 391 | 0.570 |
Why?
|
| Cardiomyopathies | 3 | 2016 | 291 | 0.490 |
Why?
|
| Radiation Protection | 1 | 2016 | 27 | 0.470 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 189 | 0.460 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 6 | 0.460 |
Why?
|
| Cardiology Service, Hospital | 1 | 2015 | 6 | 0.460 |
Why?
|
| Cardiac Volume | 1 | 2015 | 33 | 0.450 |
Why?
|
| Taxoids | 1 | 2015 | 126 | 0.430 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 3110 | 0.430 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 939 | 0.430 |
Why?
|
| Myocardial Ischemia | 6 | 2005 | 140 | 0.420 |
Why?
|
| Echocardiography, Doppler, Color | 5 | 2004 | 73 | 0.400 |
Why?
|
| Heart Ventricles | 3 | 2016 | 650 | 0.390 |
Why?
|
| Physical Examination | 3 | 2020 | 144 | 0.390 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 394 | 0.380 |
Why?
|
| Echocardiography, Stress | 4 | 2005 | 15 | 0.360 |
Why?
|
| Humans | 56 | 2024 | 93515 | 0.360 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2021 | 332 | 0.350 |
Why?
|
| Phenethylamines | 2 | 2000 | 6 | 0.330 |
Why?
|
| Ultrasonography | 5 | 2020 | 702 | 0.330 |
Why?
|
| Potassium Channel Blockers | 2 | 2000 | 59 | 0.330 |
Why?
|
| Neoplasms | 6 | 2023 | 3169 | 0.320 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2000 | 76 | 0.320 |
Why?
|
| Mitral Valve | 3 | 2005 | 225 | 0.290 |
Why?
|
| Heart Failure | 1 | 2019 | 1386 | 0.290 |
Why?
|
| Sulfonamides | 2 | 2000 | 331 | 0.280 |
Why?
|
| Myocardial Contraction | 5 | 2004 | 188 | 0.270 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2802 | 0.270 |
Why?
|
| Image Enhancement | 4 | 2005 | 505 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2024 | 626 | 0.250 |
Why?
|
| United States | 8 | 2024 | 7622 | 0.240 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2005 | 179 | 0.220 |
Why?
|
| Heart Atria | 3 | 2021 | 248 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 7 | 2021 | 262 | 0.220 |
Why?
|
| Early Diagnosis | 2 | 2018 | 135 | 0.220 |
Why?
|
| Sensitivity and Specificity | 9 | 2008 | 1922 | 0.210 |
Why?
|
| Atrial Function, Left | 2 | 2021 | 36 | 0.200 |
Why?
|
| Cardiologists | 1 | 2023 | 8 | 0.200 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 109 | 0.200 |
Why?
|
| Atrial Flutter | 2 | 2000 | 41 | 0.200 |
Why?
|
| Movement | 1 | 2005 | 304 | 0.200 |
Why?
|
| American Heart Association | 1 | 2024 | 106 | 0.200 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2004 | 97 | 0.200 |
Why?
|
| Aorta | 1 | 2004 | 273 | 0.200 |
Why?
|
| Inservice Training | 1 | 2003 | 36 | 0.200 |
Why?
|
| Electric Countershock | 2 | 2000 | 74 | 0.190 |
Why?
|
| Exercise Test | 1 | 2003 | 152 | 0.180 |
Why?
|
| Women's Health | 1 | 2003 | 107 | 0.180 |
Why?
|
| Thrombosis | 3 | 2016 | 309 | 0.180 |
Why?
|
| Transillumination | 1 | 2021 | 6 | 0.180 |
Why?
|
| Algorithms | 4 | 2019 | 1953 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 149 | 0.170 |
Why?
|
| Electrocardiography | 2 | 2003 | 493 | 0.170 |
Why?
|
| Atrial Fibrillation | 3 | 2000 | 417 | 0.170 |
Why?
|
| Contrast Media | 7 | 2005 | 988 | 0.170 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 203 | 0.160 |
Why?
|
| Tachycardia | 1 | 2000 | 38 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2585 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 202 | 0.160 |
Why?
|
| Heart Conduction System | 1 | 2000 | 133 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 225 | 0.150 |
Why?
|
| Female | 24 | 2024 | 48702 | 0.150 |
Why?
|
| Nuclear Family | 1 | 2019 | 92 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2014 | 157 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2019 | 111 | 0.140 |
Why?
|
| Hemothorax | 1 | 2018 | 12 | 0.140 |
Why?
|
| Heart Massage | 1 | 2018 | 11 | 0.140 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 254 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 375 | 0.140 |
Why?
|
| Ventricular Fibrillation | 1 | 2018 | 67 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2016 | 145 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 452 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 300 | 0.130 |
Why?
|
| Consensus | 2 | 2016 | 368 | 0.130 |
Why?
|
| Pedigree | 1 | 2019 | 961 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2017 | 191 | 0.120 |
Why?
|
| Parents | 1 | 2019 | 292 | 0.120 |
Why?
|
| Anticoagulants | 2 | 2018 | 457 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 1713 | 0.120 |
Why?
|
| Risk Factors | 5 | 2019 | 5899 | 0.120 |
Why?
|
| Radiation, Ionizing | 1 | 2016 | 123 | 0.120 |
Why?
|
| Pandemics | 1 | 2021 | 873 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2016 | 621 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2016 | 229 | 0.110 |
Why?
|
| Myocardium | 4 | 2011 | 570 | 0.110 |
Why?
|
| Phenotype | 2 | 2019 | 2544 | 0.110 |
Why?
|
| Male | 23 | 2024 | 44557 | 0.110 |
Why?
|
| Incidence | 3 | 2016 | 1701 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2018 | 311 | 0.110 |
Why?
|
| Documentation | 1 | 2014 | 97 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2005 | 1261 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2003 | 1090 | 0.100 |
Why?
|
| Feasibility Studies | 6 | 2005 | 756 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 226 | 0.100 |
Why?
|
| Tunica Intima | 3 | 2008 | 61 | 0.100 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2014 | 122 | 0.100 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 338 | 0.100 |
Why?
|
| Echocardiography, Doppler | 2 | 2003 | 135 | 0.100 |
Why?
|
| Middle Aged | 15 | 2024 | 27573 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2715 | 0.090 |
Why?
|
| Aged | 13 | 2024 | 20434 | 0.090 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 630 | 0.090 |
Why?
|
| Education, Medical, Graduate | 1 | 2016 | 425 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 1762 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 326 | 0.090 |
Why?
|
| Radiology | 2 | 2014 | 192 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2008 | 2441 | 0.080 |
Why?
|
| Office Visits | 2 | 2008 | 47 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2011 | 92 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 1103 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 485 | 0.080 |
Why?
|
| Systole | 2 | 2011 | 83 | 0.080 |
Why?
|
| Observer Variation | 4 | 2024 | 570 | 0.080 |
Why?
|
| Swine | 4 | 2004 | 588 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2003 | 383 | 0.080 |
Why?
|
| Heart | 3 | 2021 | 522 | 0.080 |
Why?
|
| Biomarkers | 2 | 2014 | 1910 | 0.070 |
Why?
|
| Equipment Design | 3 | 2005 | 416 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2009 | 78 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2005 | 822 | 0.070 |
Why?
|
| Fluorocarbons | 3 | 2003 | 50 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2008 | 27 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 225 | 0.070 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 100 | 0.070 |
Why?
|
| Prevalence | 3 | 2011 | 1321 | 0.060 |
Why?
|
| Professional Competence | 1 | 2007 | 66 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2021 | 10164 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 2465 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 114 | 0.060 |
Why?
|
| Endocardium | 2 | 2004 | 78 | 0.060 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2003 | 60 | 0.060 |
Why?
|
| Cholesterol | 1 | 2008 | 364 | 0.060 |
Why?
|
| Dipyridamole | 1 | 2005 | 12 | 0.060 |
Why?
|
| Esophageal Perforation | 1 | 2005 | 18 | 0.060 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2002 | 14 | 0.060 |
Why?
|
| Health Personnel | 1 | 2007 | 234 | 0.060 |
Why?
|
| Puerperal Disorders | 1 | 2005 | 34 | 0.060 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 133 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 18 | 0.050 |
Why?
|
| Ventricular Dysfunction | 2 | 2004 | 24 | 0.050 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 107 | 0.050 |
Why?
|
| Skin | 1 | 2008 | 578 | 0.050 |
Why?
|
| Adult | 10 | 2014 | 27918 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 302 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2005 | 223 | 0.050 |
Why?
|
| Myxoma | 1 | 2004 | 28 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2004 | 46 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 27 | 0.050 |
Why?
|
| Dobutamine | 1 | 2003 | 38 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2002 | 179 | 0.050 |
Why?
|
| Hospitals, General | 1 | 2003 | 11 | 0.050 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2003 | 7 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2008 | 576 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 181 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2005 | 884 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2005 | 238 | 0.050 |
Why?
|
| Heart Function Tests | 1 | 2003 | 28 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2008 | 624 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2004 | 250 | 0.050 |
Why?
|
| Streptokinase | 1 | 2001 | 11 | 0.040 |
Why?
|
| Heart Rate | 2 | 2003 | 505 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2002 | 45 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2003 | 147 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2003 | 151 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2001 | 94 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2021 | 34 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2003 | 176 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2003 | 1917 | 0.040 |
Why?
|
| Food-Drug Interactions | 1 | 2000 | 19 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2004 | 378 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 307 | 0.040 |
Why?
|
| Electrophysiology | 1 | 2000 | 390 | 0.040 |
Why?
|
| Students, Medical | 1 | 2005 | 435 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2001 | 239 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 4560 | 0.040 |
Why?
|
| Sex Factors | 1 | 2003 | 1105 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2484 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 829 | 0.040 |
Why?
|
| Acoustics | 3 | 2003 | 46 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 328 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1546 | 0.040 |
Why?
|
| Tunica Media | 2 | 2008 | 16 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 990 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 469 | 0.030 |
Why?
|
| Animals | 5 | 2004 | 28155 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 1053 | 0.030 |
Why?
|
| Recurrence | 1 | 2000 | 1190 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2000 | 1729 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 39 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 194 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 1139 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 118 | 0.030 |
Why?
|
| Computer Systems | 1 | 2014 | 64 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2018 | 269 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 337 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2004 | 95 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2019 | 970 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 217 | 0.020 |
Why?
|
| Microspheres | 2 | 2003 | 88 | 0.020 |
Why?
|
| Reference Values | 2 | 2004 | 608 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 537 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 7061 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2011 | 172 | 0.020 |
Why?
|
| Age Factors | 2 | 2004 | 1906 | 0.020 |
Why?
|
| Wisconsin | 1 | 2008 | 44 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1985 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 76 | 0.020 |
Why?
|
| Health Behavior | 1 | 2008 | 182 | 0.020 |
Why?
|
| Motivation | 1 | 2008 | 310 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 2004 | 26 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2005 | 231 | 0.010 |
Why?
|
| Myocardial Reperfusion | 1 | 2004 | 24 | 0.010 |
Why?
|
| Illinois | 1 | 2005 | 520 | 0.010 |
Why?
|
| Transducers | 1 | 2003 | 37 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 212 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 228 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 775 | 0.010 |
Why?
|
| Computing Methodologies | 1 | 2002 | 8 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 119 | 0.010 |
Why?
|
| Minority Groups | 1 | 2004 | 149 | 0.010 |
Why?
|
| Adolescent | 2 | 2005 | 9606 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 87 | 0.010 |
Why?
|
| Albumins | 1 | 2002 | 123 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 85 | 0.010 |
Why?
|
| Chicago | 1 | 2003 | 1464 | 0.010 |
Why?
|
| Software | 1 | 2002 | 670 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 3830 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 3147 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2002 | 1931 | 0.010 |
Why?
|
| Prognosis | 1 | 2005 | 3911 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2495 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 5410 | 0.010 |
Why?
|